trending Market Intelligence /marketintelligence/en/news-insights/trending/dorkxqwfm0fypfrabhzfew2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Teva launches generic version of Eisai, Helsinn's Aloxi in US

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Teva launches generic version of Eisai, Helsinn's Aloxi in US

Teva Pharmaceutical Industries Ltd. launched a generic version of Eisai Co. Ltd. and Helsinn Healthcare SA's Aloxi injection in the U.S.

Aloxi, known chemically as palonosetron hydrochloride, is used to prevent nausea and vomiting in adults after cancer chemotherapy with a moderate or high risk of causing nausea and vomiting. It is also given to prevent nausea and vomiting up to 24 hours after surgery.

In May 2017, a U.S. federal appeals court ruled, reversing a previous judgment, that the Israeli drugmaker's generic version of palonosetron does not infringe on the patents covering Aloxi to treat nausea and vomiting due to chemotherapy.

Helsinn Healthcare filed a petition for a rehearing of the patent case but the U.S. Court of Appeals for the Federal Circuit denied the motion in January.

Aloxi injection had annual sales of about $459 million in the U.S., Teva said in a news release, citing IMS data as of November 2017.